Even prior to ORAL Surveillance, concerning safety signals appeared during the trials of Eli Lilly’s Olumiant (Baricitinib) regarding increased risk of venous thromboembolism (VTE), suggesting a possible class effect of JAK inhibitors, rather than a risk associated solely with tofacitinib and strong JAK1/JAK3 inhibition [8]. This evidence concerns the gene JAK3 and venous thromboembolism.